Last legally reviewed: August 31, 2026. Current federal effective date: November 12, 2026. Pending: a Senate-passed partial extension to December 11, 2026, which is not law as of this update.
Quick answer
There is no federal ban on hemp. What Congress actually did in November 2025 was rewrite the federal definition of hemp so narrowly that, once it takes effect, many intoxicating hemp products, most converted cannabinoids like delta-8, high-THCA flower, and potentially a meaningful share of ordinary full-spectrum CBD products will fall outside the definition of hemp and lose their exemption from the Controlled Substances Act. The change is already law, scheduled to take effect November 12, 2026. As of August 31, 2026, the Senate has passed a short extension to December 11 as part of a funding bill, but that is not yet law because the House has not agreed. For a Shopify brand, the important part is that this is not only a legal question. It is an ecommerce infrastructure problem that touches your catalog, your payments, your shipping rules, your subscriptions, and your product pages all at once, and the brands that prepare on that basis will come through it in far better shape. For hemp brands using the regulatory change as a reason to move into non-infused wellness, supplements, functional beverages, personal care, or other conventional CPG categories, the challenge is bigger than replacing a SKU: the product architecture, positioning, subscriptions, payments, retention, and storefront usually need to be rebuilt around a new reason to buy.
This article explains the operational and ecommerce side of these rules. It is general information, not legal advice, and the situation is changing quickly. Confirm your specific products, claims, and shipping states with qualified counsel.
What Congress actually did, and what it didn't
On November 12, 2025, the FY2026 appropriations package (Public Law 119-37) was signed into law. Section 781 of that law rewrites the federal definition of hemp in the U.S. Code, and the change becomes effective 365 days later, on November 12, 2026. This is enacted law, not a proposal, an FDA rule, a DEA action, or a Farm Bill draft. The only open question now is whether Congress changes or delays it before it takes effect.
It is worth being precise, because "Congress banned hemp" is both inaccurate and unhelpful. The new definition explicitly protects industrial hemp: stalk and fiber, grain, seed and seed oil, and research plants all survive. What the law restructures is the hemp-derived cannabinoid consumer market, the gummies, drinks, tinctures, flower, and vapes that grew up under the 2018 Farm Bill. A more accurate way to describe it is a federal redefinition that changes the framework that allowed many intoxicating hemp-derived products to qualify as hemp under the 2018 definition, what lawmakers and regulators have often called the intoxicating-hemp loophole, and that pulls a large part of today's cannabinoid product market outside the legal category of hemp. The Congressional Research Service describes competing stakeholder positions on this rather than treating either framing as settled, and reaches the same qualitative conclusion about the scale of the impact. (CRS)
The three changes that actually matter
Under the 2018 Farm Bill, cannabis and its derivatives counted as hemp if they contained no more than 0.3% delta-9 THC by dry weight. That definition helped enable the modern hemp-derived delta-8, delta-9, and THCA markets by making delta-9 THC concentration, not total intoxicating cannabinoid content, the federal dividing line between hemp and marijuana. The 2025 law changes it in three ways that matter to any brand selling cannabinoid products.
| Change | What it does | Who it hits hardest |
|---|---|---|
| Total THC, including THCA | The plant definition moves from delta-9 alone to total tetrahydrocannabinols, expressly including THCA, which converts to delta-9 when heated | High-THCA "hemp" flower, whose main legal argument relied on measuring only delta-9 |
| 0.4 mg per container | A finished product is excluded from hemp if it contains more than 0.4 mg combined covered cannabinoids per retail container, meaning total THC including THCA plus other cannabinoids determined to have, or marketed as having, THC-like effects | Nearly every intoxicating product, and many low-dose and full-spectrum products too |
| Synthesized and converted cannabinoids | Final products are excluded if they contain cannabinoids that cannot be naturally produced by the plant, or that occur naturally but were synthesized or manufactured outside it | Converted delta-8, delta-10, HHC, THC-O, and similar novel cannabinoids, regardless of THC level |
There are two different THC thresholds here, and readers constantly confuse them. The 0.3% total THC by dry weight applies to whether the cannabis plant and its derivatives fit the general hemp definition. The 0.4 mg-per-container test is a separate exclusion aimed at final hemp-derived cannabinoid consumer products. They are not interchangeable, and a product can clear one while failing the other.
The 0.4 mg figure deserves a second look, because it is easy to misread. That is 0.4 milligrams of combined covered cannabinoids per container, not per serving, not 0.4%, not 4 mg. It is tiny. For perspective, a hemp beverage sold under Minnesota's regulated market can contain up to 10 mg of THC per container, which is 25 times the new federal threshold. A single 5 mg gummy is more than 12 times over it. So this is not narrowly a rule about extreme delta-8 vapes. It reaches very low-dose products as well.
The synthetic exclusion is a separate test, and it is easy to miss. A product can contain almost no THC and still fail the definition purely because of how its cannabinoids were made. Commercial delta-8 is typically produced by chemically converting hemp-derived CBD, because delta-8 occurs naturally only in trace amounts, and the new law was written specifically to close that route.
Current law versus the November 12 rules
Because this is contentious and moving quickly, it is worth separating what is true today from what changes on the effective date. Everything in the right column takes effect November 12, 2026 unless Congress changes the law first.
| Question | Through November 11, 2026 | Beginning November 12 unless Congress acts |
|---|---|---|
| General federal hemp threshold | 0.3% or less delta-9 THC by dry weight | 0.3% or less total THC, including THCA |
| Converted cannabinoids | Existing law and court interpretation apply; state rules vary | Certain synthesized or manufactured cannabinoids expressly excluded |
| Finished cannabinoid products | No new 0.4 mg federal hemp cap yet | More than 0.4 mg combined covered cannabinoids per container excluded |
| State restrictions | Still apply | Still apply |
| FDA food and supplement rules | Still apply | Still apply |
Why this reaches ordinary CBD, not just delta-8
This is the part that most coverage gets wrong. The 0.4 mg limit applies to a final hemp-derived cannabinoid product, not only to products marketed to get you high. A full-spectrum CBD tincture, gummy, or topical can contain small, naturally occurring amounts of THC, and across an entire retail container those amounts can easily exceed 0.4 mg total. The result is that a non-intoxicating wellness product could lose federal hemp status under the same rule aimed at delta-8.
You do not have to take an advocate's word for that. President Trump's December 18, 2025 executive order specifically acknowledged that some full-spectrum CBD products will become controlled as marijuana when Section 781 takes effect because they exceed the new per-container threshold, and directed officials to work with Congress to preserve access to appropriate full-spectrum products while restricting higher-risk ones. That executive order did not repeal or rewrite the statute, and it could not, but it does confirm that the text reaches further than "intoxicating hemp." So the clean-sounding line, "the law only bans intoxicating products," is not accurate as written.
What happens to a product that stops qualifying as hemp
This is why the redefinition is more serious than a labeling change. The Controlled Substances Act carves hemp, and the THC in hemp, out of the definition of marijuana. If a product no longer fits the statutory definition of hemp, that carve-out can disappear, and the Congressional Research Service has explained that products that lose the hemp exemption may instead become subject to the Controlled Substances Act as marijuana or regulated THC, depending on the product. (CRS) In other words, the risk is not that the FDA asks you to change your packaging. It is that the product loses its legal category. Federal enforcement priorities after the effective date remain genuinely uncertain, which is its own planning problem, but the category shift is the thing to understand.
What happened to the court rulings that said delta-8 could be hemp?
If you built a business on the idea that hemp-derived delta-8 is federally legal, that idea came partly from the courts, and it is worth understanding why it no longer settles the question. Federal appellate courts interpreting the 2018 Farm Bill, including the Ninth Circuit in AK Futures v. Boyd Street Distro, concluded that certain hemp-derived delta-8 products could fall within the federal hemp definition if they satisfied the statute's 0.3% delta-9 threshold, and the Fourth Circuit later agreed with that statutory reading over a contrary DEA interpretation. (Fourth Circuit) The 2025 law does not overrule those courts. Congress changed the statutory language they were interpreting. Once the new definition takes effect, those cases no longer answer the same legal question, because the dividing line they relied on, delta-9 concentration alone, is no longer the test.
The date is still November 12, and the "it's been delayed" headlines are ahead of the law
There is a lot of confused reporting here, so it is worth stating carefully what is and isn't true as of August 31, 2026.
The new federal hemp definition remains scheduled to take effect on November 12, 2026. On August 8, 2026, the Senate passed a government funding bill by a vote of 90 to 6 that includes language postponing part of the hemp change until December 11, 2026, and an effort led by Senators Budd and Ricketts to strip that delay failed 61 to 32. (Roll Call) But a Senate vote is not law. The House has not agreed, so as of today the December 11 extension has not taken effect. Two further points matter. First, the Senate provision delays only the portion affecting naturally derived cannabinoids, while the crackdown on synthetic and converted cannabinoids would still begin November 12, a distinction confirmed in the Senate's own description of the bill. (Senate statement) Second, the longer delays you may have seen, the bills that would push implementation to 2027 or 2028, have not become law either. So the accurate statements are narrow: the new definition is scheduled for November 12; the Senate has passed a partial one-month delay that still needs the House; nothing has been pushed to 2028.
Complicating all of it, the FDA missed a statutory deadline. Congress gave the agency 90 days after enactment, a deadline that fell on February 10, 2026, to publish key lists: which cannabinoids can occur naturally, which have THC-like effects, and further guidance on what counts as a "container." As of the Congressional Research Service's August 17, 2026 update, those lists still had not been published. (CRS) The law does supply its own baseline definition of a container, generally the innermost package in direct contact with the product at retail, such as a jar, bottle, can, or cartridge, and excluding bulk shipping packaging. But the missing FDA guidance leaves real ambiguity in exactly the places brands need certainty.
Why the federal hemp rules still aren't settled
Congress has enacted the new hemp definition, but it has not reached a durable consensus on how the cannabinoid market should be regulated once that definition takes effect. Since the law passed, lawmakers from both parties have introduced bills to delay, replace, or narrow it. The Senate has now gone further and passed a temporary extension through December 11, 2026 for naturally derived products while preserving restrictions on synthetic derivatives, but the House has not agreed to that language. As a result, November 12 remains the controlling legal date today, even though there is a meaningful possibility that Congress changes the timeline or the framework before then.
The FDA's missed deadline adds to that unsettled picture. Congress told the agency to publish key cannabinoid classifications and container guidance within 90 days, and those details are still incomplete. Put the pieces together and a genuine pattern emerges, not just media noise: a law enacted, implementation delayed a year, the required agency detail still missing, multiple bipartisan bills to delay or rewrite it, a Senate-passed temporary delay, and the House still unresolved.
Underneath it sits a real policy disagreement. Supporters of the new definition argue that the 2018 framework let intoxicating products be sold outside licensed marijuana systems, often without consistent age, testing, potency, or packaging rules. Opponents argue that the 0.4 mg-per-container rule reaches far beyond high-potency intoxicants, and would wipe out state-regulated low-dose hemp markets and some non-intoxicating full-spectrum CBD products along with them. The Senate's split approach, delaying naturally derived products while keeping the synthetic crackdown, is Congress trying to hold both concerns at once.
The practical takeaway for brands is straightforward. The new federal definition is real law and the November 12 deadline is real, but the final implementation path is still moving, and Congress has repeatedly signaled it may delay or rewrite parts of the framework before the deadline arrives. Prepare for the enacted law without assuming the current November framework will be the final version.
The part the legal explainers miss: this is an ecommerce infrastructure problem
Most coverage frames this as legal versus banned. For a DTC brand on Shopify, that framing is close to useless, because the real question is not a single yes or no. It is four overlapping systems, and a product can pass one and fail another.
| Layer | The question it asks |
|---|---|
| 1. Controlled Substances Act | Does this product still qualify as hemp, or has the new definition pushed it into controlled territory? |
| 2. FDA | Can this ingredient be lawfully sold as a food, supplement, cosmetic, or drug, separate from whether it is "hemp"? |
| 3. State law | Can this specific SKU be manufactured, sold, and shipped into this particular state? |
| 4. Platform and payments | Will Shopify, your payment processor, your ad networks, and your carriers actually support it? |
That fourth layer is where a lot of brands get caught, because it is invisible until it breaks. And the FDA layer catches people by surprise too: the 2018 Farm Bill removed qualifying hemp from controlled-substance status, but it never made CBD a legal food additive or dietary supplement ingredient. The FDA's position remains that CBD and THC generally cannot be marketed as dietary supplements or added to conventional food in interstate commerce (FDA), and the only cannabis-derived drug it has approved is Epidiolex, alongside a few synthetic cannabis-related drugs. (FDA) Controlled-substance legality and FDA product legality are different questions, and this redefinition changes the first without fixing the second.
The Shopify specifics every hemp and CBD brand has to get right
Here is the practical reality on the platform, and it is more nuanced than "Shopify allows CBD" or "Shopify bans CBD," both of which are wrong.
Shopify does support hemp and hemp-derived product merchants, on the condition that the product is legal where you operate and where you ship, and U.S. sellers have to make specific compliance representations about licensing, sourcing, testing, labeling, and THC thresholds. (Shopify) But Shopify Payments does not process hemp, CBD, or THC transactions. Those sales have to run through a third-party payment provider that accepts the category, and Shopify itself points merchants to processors like DigiPay and Bankful, with approval depending on the processor's underwriting. (Shopify) That has direct consequences for your economics and your checkout: higher fees, reserve requirements, approval risk, and gateway reliability all become live issues.
There is a trap inside this for wellness and supplement brands especially. If a store currently runs on Shopify Payments and decides to add even a single CBD SKU, it can jeopardize Shopify Payments eligibility for the entire store, and Shopify's own guidance is to consider either moving the whole store to a qualifying third-party processor or standing up a separate hemp store. "We'll just add one CBD product" is a payment-architecture decision, not a merchandising one. Shopify also expects merchants to comply with the laws of both their location and each shipping destination, which is why a serious hemp build needs product-specific shipping restrictions and, where applicable, age controls, certificates of analysis, batch information, and any state-required disclosures. Selling into a state where a product is not legal can violate Shopify's terms and put the account at risk, so the platform pushes the legal burden squarely onto the merchant.
State law is already a patchwork, and it decides where you can ship
"Federally legal hemp" never meant "legal to sell in all 50 states," and in 2026 the gap between states is wide. Four states show how different the models already are.
- California effectively requires hemp foods, beverages, and supplements to contain no detectable THC or other intoxicating cannabinoids, with a 21-and-over age requirement and a cap of five servings per package. It does not ban non-intoxicating CBD with no detectable THC, and intoxicating products stay inside the licensed cannabis system. (CDPH) This is not a law-on-paper example either; California's ABC was still conducting hundreds to more than 1,000 hemp compliance visits per month through much of 2026. (California ABC)
- Texas now treats delta-8 as controlled outside of naturally occurring trace amounts. After the Texas Supreme Court's May 2026 decision in the Sky Marketing case, the state's schedule clarifying delta-8 as controlled took effect July 31, 2026. A retailer should no longer assume hemp delta-8 is legal in Texas just because it met the old federal delta-9 threshold. (Texas DSHS)
- Minnesota regulates rather than prohibits, allowing lower-potency hemp edibles up to 5 mg THC per serving and 50 mg per package, and beverages up to 10 mg per container, for buyers 21 and over, through a licensed market. The state has licensed more than 1,500 hemp-derived THC businesses. (Minnesota OCM)
- Tennessee built a licensed and taxed market with brand registration and testing, generally recognizing products at or under 0.3% total THC while prohibiting certain synthetics, and it requires even out-of-state suppliers shipping in to hold the appropriate license. By early July 2026, more than 1,300 businesses had earned the new state hemp license. (Tennessee ABC)
One common misunderstanding is worth clearing up: the 2018 Farm Bill bars states from blocking the transportation of compliant hemp through their territory, but that is not the same as requiring every state to allow retail sale of every hemp product. Transport-through and sell-into are different questions, which is exactly why California, Texas, Minnesota, and Tennessee can all coexist with such different rules. For an ecommerce brand, the practical result is that compliance is a SKU-by-SKU and state-by-state matter, and your store has to enforce it at the shipping and checkout level, not just in a disclaimer.
What the new hemp definition does not change
Because readers conflate all of these, it is worth being explicit about what this law leaves untouched.
- It does not legalize CBD in food or dietary supplements under FDA law.
- It does not override stricter state product laws.
- It does not make industrial hemp illegal.
- It does not guarantee any particular federal enforcement priority after the effective date.
- It does not, by itself, resolve every cannabinoid's status, because the FDA lists Congress required are still missing.
- It does not automatically authorize products under state marijuana programs.
- It is separate from marijuana scheduling or rescheduling, which is its own legal question.
Liquid Lemon has worked with hemp and cannabinoid brands including Snoozy, WYLD, Trail Magic, Highly Casual, and others across Shopify design and CRO, storefront builds, lifecycle email and SMS, automated flows, and retention, plus paid social for select brands. We began working with Snoozy in 2021, so we have watched the category evolve from the early post-Farm Bill growth period into the regulatory uncertainty brands are navigating now.
Three strategic paths hemp brands are weighing
Everything above is deliberately neutral, and it should be, because no one should make a business decision off a headline. But whatever Congress ultimately does, some brands are already using the uncertainty to reconsider whether cannabinoids need to remain the center of the business at all. This is not hypothetical. In its August 13, 2026 second-quarter results, Charlotte's Web reported that California, roughly 10% of its revenue, was materially affected by the state's hemp restrictions, and that it was launching reformulated products for that market. (Charlotte's Web) When a category leader reformulates, smaller brands tend to feel the same pressure sooner. Broadly, brands are weighing three paths, and they are not equally viable for everyone.
- Reformulate within hemp or CBD. For brands that still want cannabinoid products and can design around the new federal thresholds and their states' rules. The regulatory burden changes, it does not disappear.
- Move into licensed cannabis. For businesses where intoxicating products are the core proposition and a state cannabis pathway is commercially viable. This is a heavier lift than a Shopify SKU change implies, because state cannabis systems can require licensed manufacturing and distribution, state-specific testing, track-and-trace, cannabis-specific packaging, licensed retailers, and no interstate commerce.
- Pivot into non-infused CPG. For brands whose real asset is the audience, the distribution, the formulation expertise, or the wellness positioning rather than THC itself. This can be the path that preserves the most existing brand, customer, and distribution value when THC itself is not the core reason customers buy, and it is the one we are especially equipped to help with.
If you're pivoting from hemp to non-infused CPG, don't treat it as a product swap
"Non-infused" is not one product. It is a set of adjacent categories a hemp or CBD brand can credibly move into, depending on what the brand already stands for: functional beverages without cannabinoid actives, hydration and electrolytes, sleep and calm products formulated without hemp cannabinoids, functional-mushroom or adaptogen products where appropriately formulated and substantiated, vitamins and supplements, personal care and topical wellness, and everyday CPG like snacks. The important caveat is that none of these are unregulated. Supplements, foods, and cosmetics each carry their own FDA and state requirements, and health claims carry their own risk. The regulatory burden changes; it does not disappear.
The bigger point is that a real pivot touches far more than the formula. Done properly it means decisions across brand architecture, whether to keep the current brand or launch a sub-brand or a new brand, customer migration, category positioning and the reason to buy, a Shopify catalog rebuild, product-page education, subscriptions, email and SMS segmentation, SEO migration, paid-media account and creative transition, payment-provider reconsideration, and inventory transition. The legal sites will tell you what becomes risky. The harder and more valuable question is how to turn the customer base you already have into a conventional CPG or wellness business, and that is a build problem, not a legal one. We cover that operational playbook in depth in how hemp brands can pivot to non-infused products.
That distinction matters because we have spent years working inside the retention layer of hemp brands: the valuable asset is often not the cannabinoid SKU itself, but the customer relationship, purchase history, subscription behavior, creative learnings, and owned audience built around it.
A hemp pivot doesn't mean starting from zero
The mistake that destroys value is treating a pivot as a teardown. Even when the product has to change, the brand usually still owns a great deal that carries forward: the email and SMS list, the subscription relationships, brand awareness, domain authority and organic rankings, reviews and testimonials that still apply, creative assets, retailer and distributor relationships, creator and influencer relationships, first-party customer data, Shopify order history, customer cohorts, and hard-won paid-media learnings. The job is to preserve the assets that still have value while separating them from the products, claims, and infrastructure that no longer fit the next model.
Which path is right depends on where your real moat sits.
| If your brand's moat is... | Likely path |
|---|---|
| Cannabinoid formulation or intoxication | Evaluate licensed cannabis or a compliant reformulation |
| An existing wellness audience | A non-infused wellness or CPG pivot may preserve more enterprise value |
| Retail distribution | Build products your existing buyers can keep carrying |
| Subscription base and customer list | Design the new line around continuity and retention |
| SEO and domain authority | Preserve URLs and content where relevant and migrate product intent carefully |
| Strong brand but weak product legality | Keep the brand equity, rebuild the offer |
What to actually do now
Because the date is unstable and the guidance is incomplete, the right posture is to prepare so you are ready to ship changes on the effective date, while sequencing the work so a delay buys runway rather than wasting effort. Everything here is worth doing regardless of the exact date, because it also makes the business more durable.
- Audit every SKU against both new tests. Flag anything over 0.4 mg combined covered cannabinoids per container, and separately flag anything using converted or synthesized cannabinoids, which can fail on production method alone.
- Decide the product path. For at-risk SKUs, reformulate toward products designed to meet the new federal thresholds, while separately validating FDA and state-law requirements, or evaluate whether a separately licensed state cannabis channel is commercially and legally viable where state law permits it. Product development is the longest lead time, so start here.
- Fix the payment architecture. Confirm your processor supports the category, and if you run mixed products, decide deliberately between a qualifying third-party processor and a separate store before it forces your hand.
- Enforce compliance in the store, not the footer. Set shipping profiles by destination state, add age controls where required, and make certificates of analysis and batch information accessible on the product page.
- Protect subscriptions. A SKU that is compliant when a customer subscribes can become non-compliant mid-term. Map subscribed products to replacements so recurring revenue converts instead of breaking.
- Update stale claims and SEO copy. Pages that say "Farm Bill compliant" or lean on the old delta-9 framing can become factually wrong overnight. Fix product claims and any "federally legal" language before the date, not after.
- Protect the customer and email data. Your list, subscription base, and reviews are the most valuable things you own. Whatever you sell next, migrate that data cleanly so retention carries forward rather than resetting.
Most of this is a Shopify build and retention problem, which is the work we do every day. Rebuilding a compliant catalog and the payment and shipping architecture behind it is a replatform and rebuild project, and protecting the customers and subscription revenue through the change is a retention one. The same logic that makes supplement and wellness brands live or die on repeat revenue applies here, and the store still has to convert the traffic you bring to it.
The redefinition is really an ecommerce infrastructure change wearing a legal headline, and the brands that come through it best will be the ones that decide early whether cannabinoids still belong at the center of the business, then rebuild around that answer. If you're pivoting a hemp or CBD brand into a non-infused product line, Liquid Lemon can rebuild the Shopify storefront, catalog, payments, subscriptions, and retention system around the next version of the business, while preserving the audience and data you already own. Talk through your product pivot, or start a sprint, and we will map what to keep, what to rebuild, and in what order.
Andrew Zam is co-founder of Liquid Lemon, a Shopify / Shopify Plus design + development studio that has worked with hemp and cannabinoid brands including Snoozy, WYLD, Trail Magic, Highly Casual, and others across Shopify design and CRO, retention, lifecycle email and SMS, and paid acquisition. This article is general information about running a Shopify brand through a regulatory change, not legal advice. It reflects the law and reporting available as of August 31, 2026; confirm current status and your specific products, claims, and shipping states with qualified counsel.
